Clearmind Medicine Inc. (NASDAQ:CMND) Sees Large Decrease in Short Interest

Posted by Carolyn Dwyer on Mar 5th, 2025

Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 274,600 shares, a decrease of 16.0% from the January 31st total of 326,800 shares. Based on an average daily trading volume, of 955,100 shares, the days-to-cover ratio is presently 0.3 days. Currently, 9.2% of the shares of the stock are short sold.

Clearmind Medicine Price Performance

Clearmind Medicine stock traded up $0.02 during mid-day trading on Wednesday, reaching $1.16. The company had a trading volume of 19,266 shares, compared to its average volume of 1,069,774. The stock’s 50-day simple moving average is $1.41 and its 200-day simple moving average is $1.37. The company has a market capitalization of $4.95 million, a P/E ratio of -0.62 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.72. Clearmind Medicine has a 1 year low of $0.95 and a 1 year high of $2.30.

Clearmind Medicine (NASDAQ:CMND – Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported ($0.11) earnings per share for the quarter.

Hedge Funds Weigh In On Clearmind Medicine

An institutional investor recently raised its position in Clearmind Medicine stock. Citadel Advisors LLC increased its stake in shares of Clearmind Medicine Inc. (NASDAQ:CMND – Free Report) by 115.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,158 shares of the company’s stock after purchasing an additional 20,429 shares during the period. Citadel Advisors LLC owned 0.89% of Clearmind Medicine worth $53,000 as of its most recent SEC filing. Institutional investors and hedge funds own 96.05% of the company’s stock.

About Clearmind Medicine

(Get Free Report)

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.